An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC). If clinically validated, it could give clinicians much-needed insight into one of the most pressing challenges in oncology…
Read More
About The Author
